Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) COO Sells $135,300.00 in Stock

Key Points

• Oramed Pharmaceuticals COO Joshua Hexter sold 30,000 shares at an average price of $4.51, generating $135,300. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 1,328,130 shares.
• ORMP shares rose 0.2% to $4.49, with the stock trading between a 52-week low of $2.09 and high of $5.47. The company recently reported a quarterly EPS loss of $0.09, missing the $0.43 consensus estimate.
• Institutional investors and hedge funds own 12.73% of Oramed’s shares, while analyst sentiment remains broadly neutral, with the stock carrying an average “Hold” rating.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) COO Joshua Hexter sold 30,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $135,300.00. Following the completion of the sale, the chief operating officer directly owned 1,328,130 shares of the company's stock, valued at approximately $5,989,866.30. This represents a 2.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oramed Pharmaceuticals Trading Up 0.2%

NASDAQ ORMP traded up $0.01 on Friday, reaching $4.49. 178,322 shares of the company were exchanged, compared to its average volume of 227,288. The business's fifty day moving average price is $4.64 and its 200 day moving average price is $4.19. The stock has a market capitalization of $186.78 million, a P/E ratio of 1.09 and a beta of 1.29. Oramed Pharmaceuticals Inc. has a fifty-two week low of $2.09 and a fifty-two week high of $5.47.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by ($0.52). Equities research analysts forecast that Oramed Pharmaceuticals Inc. will post 1.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. SB Capital Management Inc acquired a new stake in Oramed Pharmaceuticals in the 4th quarter valued at about $5,415,000. Dimensional Fund Advisors LP grew its position in shares of Oramed Pharmaceuticals by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company's stock worth $538,000 after buying an additional 7,738 shares in the last quarter. Ritholtz Wealth Management purchased a new stake in shares of Oramed Pharmaceuticals during the first quarter worth approximately $529,000. Bank of America Corp DE raised its holdings in Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company's stock valued at $497,000 after acquiring an additional 3,909 shares in the last quarter. Finally, Hillsdale Investment Management Inc. acquired a new stake in Oramed Pharmaceuticals in the first quarter valued at approximately $331,000. 12.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on ORMP shares. Wall Street Zen upgraded Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Oramed Pharmaceuticals in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of "Hold".

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc NASDAQ: ORMP is a biopharmaceutical company focused on developing orally administered therapies that are traditionally delivered by injection. The company's technology is designed to protect therapeutic proteins and peptides as they pass through the digestive system and facilitate their absorption in the body.

Oramed's lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) analog candidate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.